Evidence map›Paper›PMID 41074106›Full record

ArticleVeterinary research2025

Annexin A2 facilitates porcine circovirus type 2 infection by mediating viral attachment to host cells and interacting with the capsid protein.

Yifan Jiang, Xinnuo Lei, Weijiao Liu, Siyu Cao, Qing He, Xiaohong Xie, Yang Zhan, Lei Tan, Jinhui Mai, Lingchen Yang and 3 more

Abstract read
In one paragraph

Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yifan JiangHunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Laboratory of Functional Proteomics (LFP) & Research Center of Reverse Vaccinology (RCRV), College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
Xinnuo LeiHunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Laboratory of Functional Proteomics (LFP) & Research Center of Reverse Vaccinology (RCRV), College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
Weijiao LiuHunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Laboratory of Functional Proteomics (LFP) & Research Center of Reverse Vaccinology (RCRV), College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
Siyu CaoHunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Laboratory of Functional Proteomics (LFP) & Research Center of Reverse Vaccinology (RCRV), College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
Qing HeHunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Laboratory of Functional Proteomics (LFP) & Research Center of Reverse Vaccinology (RCRV), College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
Xiaohong XieHunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Laboratory of Functional Proteomics (LFP) & Research Center of Reverse Vaccinology (RCRV), College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
Yang ZhanHunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Laboratory of Functional Proteomics (LFP) & Research Center of Reverse Vaccinology (RCRV), College of Veterinary Medicine, Hunan Agricultural University, Changsha, China. yangzhan@hunau.edu.cn.
Lei TanHunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Laboratory of Functional Proteomics (LFP) & Research Center of Reverse Vaccinology (RCRV), College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
Jinhui MaiHunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Laboratory of Functional Proteomics (LFP) & Research Center of Reverse Vaccinology (RCRV), College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
Lingchen YangHunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Laboratory of Functional Proteomics (LFP) & Research Center of Reverse Vaccinology (RCRV), College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
Aibing WangHunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Laboratory of Functional Proteomics (LFP) & Research Center of Reverse Vaccinology (RCRV), College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
Yi YangHunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Laboratory of Functional Proteomics (LFP) & Research Center of Reverse Vaccinology (RCRV), College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
Naidong WangHunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, Laboratory of Functional Proteomics (LFP) & Research Center of Reverse Vaccinology (RCRV), College of Veterinary Medicine, Hunan Agricultural University, Changsha, China. naidongwang@hunau.edu.cn.ORCID http://orcid.org/0000-0001-9660-8165

Funding

Hunan Province Technology Breakthrough Project of 2021 2021NK1030Hunan Provincial Natural Science Foundation of China 2022JJ30298Hunan Provincial Natural Science Foundation of China 2025JJ50142National Natural Science Foundation of China 32172844National Natural Science Foundation of China 32202790
6 · The paper itself

Abstract

Porcine circovirus type 2 (PCV2) causes substantial economic losses globally. Although glycosaminoglycans (GAGs) have been identified as the general cell receptors responsible for PCV2 binding and subsequent cell infection, other critical protein(s) may also be involved. Our objective was to explore key host proteins that mediate PCV2 infection. The host protein annexin A2 (ANXA2) was observed to interact with PCV2 virus-like particles (VLPs) through immunoprecipitation (IP) and liquid chromatography‒tandem mass spectrometry (LC‒MS/MS) experiments. Furthermore, knockdown of ANXA2 or the inhibitor A2ti-1 significantly reduced PCV2 replication in host cells. Notably, the addition of ANXA2-specific antibodies to cell culture or the preincubation of PCV2 with recombinant ANXA2 significantly reduced viral infection, primarily by weakening viral attachment to cells. Confocal microscopy further confirmed the colocalization of PCV2 Cap with endogenous ANXA2 in infected cells, and in vitro GST pull-down assays also demonstrated a direct interaction between these two proteins, confirming the role of ANXA2 as an attachment factor for PCV2 cellular entry. In addition, molecular docking revealed that an interface and multiple residues between PCV2 Cap and ANXA2 were involved in the interaction, which was also verified by truncation assays. In conclusion, ANXA2 on the cell surface may function as an attachment site, promoting viral binding and increasing PCV2 infectivity through interactions with Cap. These findings provide novel insights into the molecular mechanisms of PCV2 infection and new molecular targets for the development of vaccines and therapeutic strategies.

Indexed as

Annexin A2Capsid ProteinsCircoviridae InfectionsCircovirusSwine DiseasesVirus AttachmentAnimalsCell LineSwineAnnexin A2Capsid ProteinsANXA2capsidcell bindingPorcine circovirus type 2

Identifiers

PMID41074106
PMCPMC12512739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.